Inhibikase Therapeutics (IKT) Shares Outstanding (Weighted Average) (2020 - 2025)
Historic Shares Outstanding (Weighted Average) for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $90.1 million.
- Inhibikase Therapeutics' Shares Outstanding (Weighted Average) rose 91379.41% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 91379.41%. This contributed to the annual value of $23.7 million for FY2024, which is 29335.42% up from last year.
- Latest data reveals that Inhibikase Therapeutics reported Shares Outstanding (Weighted Average) of $90.1 million as of Q3 2025, which was up 91379.41% from $90.0 million recorded in Q2 2025.
- In the past 5 years, Inhibikase Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $90.1 million in Q3 2025 and a low of $4.2 million during Q4 2022
- Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $8.9 million (2024), whereas its average is $23.3 million.
- In the last 5 years, Inhibikase Therapeutics' Shares Outstanding (Weighted Average) crashed by 8319.93% in 2022 and then surged by 131210.3% in 2025.
- Inhibikase Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $18.2 million in 2021, then tumbled by 76.81% to $4.2 million in 2022, then surged by 42.74% to $6.0 million in 2023, then soared by 293.35% to $23.7 million in 2024, then soared by 279.77% to $90.1 million in 2025.
- Its Shares Outstanding (Weighted Average) was $90.1 million in Q3 2025, compared to $90.0 million in Q2 2025 and $89.5 million in Q1 2025.